Pioneering Analyzer with Advanced Biochip Technology Sets New Standard in Lab Diagnostics
Posted on 07 Jul 2025
A state-of-the-art analyzer combines advanced technology with exceptional efficiency to meet the demanding needs of modern laboratories.
Randox Toxicology (Antrim, Ireland) has launched its pioneering Evidence RABTA (Random Access Biochip Technology Analyzer), which combines advanced Biochip Array Technology with exceptional efficiency.
Biochip Array Technology is an immunoassay testing platform allowing for the simultaneous multi-analyte testing of a panel of related tests. The technology works by combining a panel of up to 48 tests on a single Biochip with a single set of reagents, controls, and calibrators. Competitive chemiluminescent immunoassays are employed for the Biochip Arrays. A light signal generated from each of the test regions on the Biochip is simultaneously detected using digital imaging technology and compared to that from a calibration curve. Available across a wide variety of matrices for forensic, clinical, and workplace toxicology, this revolutionary multi-analyte testing platform is designed to allow toxicologists to achieve a complete immunoassay profile in the initial screening phase.
Designed for seamless operation, the RABTA platform allows uninterrupted workflows and increased productivity. With rapid random-access capabilities, the analyzer provides precise and reliable results across a wide range of assays. Featuring five intuitive modules, this innovative analyzer simplifies high-throughput biological analysis, enabling clinicians to conduct complex assays quickly and accurately. Each module is tailored for specific functions, ensuring easy integration and adaptability for various applications, from diagnostics to advanced research. Its random-access capability allows simultaneous processing of multiple samples, making it an essential tool for modern laboratories.
Related Links:
Randox Toxicology
